@meditech

Human Genetics Industry: New Innovation & Perception

2021-03-01T08:44:03.374Z

Human genetics includes study of the inheritance in humans. Human genetics is broad sector which include various sub-sectors such as cytogenetics, molecular genetics, biochemistry, linical genetics, and genetic counseling and others. These sectors helps in understanding the concepts of gene structure and organization, expression of gene, detection of mutation and its analysis, linkage analysis and genetic mapping, and physical mapping among others. The study of human genetics allows to understand genetically of complexes in a diseases and epistatic interactions such as ethical, legal and social issues.

The global human genetics market is segmented on the basis of product, application and end user. Based on the product segment, market is divided into instruments, consumables, and accessories. On the basis of application the market is classified as drug development, research, forensic, and diagnostics. Based on the end user the market is classified as pharmaceutical and biotechnological companies, diagnostics centers, forensic centers, and research centers.

Get sample PDF Brochure >> https://bit.ly/3uRNjeq

Overall, a majority of survey respondents possess positive feelings about human genetic research (77 percent), although approximately 40 percent have misconceptions and even less are familiar with personalized medicine as an extension of genomics—indicating a need for further public education.

Many see genetic research as critical to improving their families’ health. For example, respondents believe researchers will use genetics to find cures for key diseases like cancer or Alzheimer’s (78 percent); that physicians will be able to use genetic information to inform their health care (71 percent); that people will learn “surprising information” about their heritage or backgrounds (69 percent); and that it will be possible to change genes in embryos to prevent severe diseases like sickle cell disease, cystic fibrosis, or muscular dystrophy (60 percent)—a surprising nod to CRISPR-Cas9.

Leading companies operating in this research are

Thermo Fisher Scientific, Inc.
Agilent Technologies, Inc.
Illumina, Inc.
Promega Corporation
General Electric
QIAGEN
Bio-Rad Laboratories, Inc.
LGC Limited
Bode Cellmark Forensics, Inc.
Horiba

To comprehend global Human genetics market dynamics in the world mainly, the worldwide market is analyzed across major global regions: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa)

Technological Advancements in Digital Pathology

2021-02-26T06:51:59.090Z

The advancement is the field of the healthcare industry is driving to the players for more research and developments for the imaging devices and the required software for the digital pathology devices. The advanced systems helps labs and hospitals to add value to the testing services as this improves the performance to influence information technology. The advanced health information technology can be deployed within pathology labs and pathology groups specifically to meet the change of patient expectations, along with this it supports the needs of physicians for optimal workflow. For instance, Aperio ePathAccess of the Leica Biosystems is software which enables sharing of the digital pathology images and case data with the experts outside the information technology network.

The concern of the people staying in the remote regions is for travelling to the urban areas for the diagnosis of the diseases. The follow up for the results becomes difficult but with the help of the digital pathology the gap between the patients and diagnosing centers is bridged. Digital pathology has helped patient to reduce their travelling time and the cost of the treatments. In addition, the digital pathology set up is easy to adopt in the rural labs and the hospitals. Thus these factors are driving the growth of the digital pathology market.

Download PDF Brochure Study Here

Moreover, scanners enables quick production of, reliable and high resolution images of cells. It helps pathologists, histologists and other medical professionals to scan slides and upload the images on the network for remote access and to collaborate it among the colleagues. The automated cellular imaging for fixing cell assays and for fluorescence, phase contrast and transmit light are provided by the scanners. The advancement in the technologies has added some more integrated software along with the scanners for future analysis, editing, managing and sharing the virtual slides. Thus, owing to these factors the market for digital pathology systems/ devices are likely to propel the growth for the market of digital pathology in the coming years.

In addition it allows the sharing of the data across the organization and other regions through the internet. Moreover, some of the companies such as Visiopharm, Indica Labs among the other market players are focused to provide software and solutions for the digital pathology. The pharmaceutical, biotechnological companies and research organizations wholly rely on software for the analysis & stereology and the quantitative digital pathology. For instance, in 2015, Visiopharm has extended to include Oncotopix Diagnostics which is robust solution for cancer diagnostics.

Some of the key factors such as efficient cost of digital pathology products, ease of virtual transportation of slides, and high efficiency of digital pathology systems are the major factors that boost the growth of the global digital pathology market. In addition, growth in adoption of digital pathology as compared to conventional pathology diagnosis drives the market growth. However, unclear reimbursement policies, dearth of skilled personnel, and unwillingness of older pathologists to adopt new technology hamper the digital pathology market growth. Moreover, rise in initiatives toward commercialization of cost-efficient digital pathology systems is anticipated to offer profitable growth opportunities for service providers in the future.

The key players operating in the field of digital pathology market worldwide include 3DHISTECH Ltd., Apollo Enterprise Imaging Corp., Huron Digital Pathology, Leica Biosystems Nussloch GmbH, Hamamatsu Photonics K.K., XIFIN, Inc., Ventana Medical Systems, Inc., Koninklijke Philips N.V., Visiopharm, Indica Labs, Inc. among others.

Explore the Potential of Teledentistry

2021-02-20T04:25:29.061Z

Oral diseases cause a major burden for various countries and affect the people throughout their lifetime by causing pain, discomfort, and disfigurement. According to the World Health Organization (WHO), oral diseases have affected approximately 3.5 billion people globally in 2020. Moreover, the WHO stated that over 530 million children worldwide suffer from dental caries. Furthermore, according to the International Journal of Health Sciences, periodontal diseases affect approximately 20–30% of population in the developed and developing nations worldwide. According to the FDI World Dental Federation, approximately 2.3 billion people suffer from dental caries of permanent teeth across the world. The treatment for oral diseases is relatively expensive and it is usually not covered by the insurance companies and healthcare ministry in majority of the countries. However, virtual visits between clinicians and patients in remote areas via communication technologies have enabled the reach of health advice and consultations in the developing nations.

Teledentistry comes under the scope of dentistry in medical care, and it has great implications both in urban and rural areas. For instance, if a patient from an urban location is in severe dental pain, they can seek the services of a dentist by using teledentistry. Similarly, for people in rural areas who may not live near a dental clinic, they can seek treatment by using teledentistry. For some people in remote locations, distance is a big hurdle in getting oral care services. All of these needs are efficiently met through teledentistry.

Download PDF Brochure of Study Here

Image Credit: dentulu

Health care has dramatically changed over the years. The credit for this change goes to the advent of telecommunications. This technology is used to send data, images, and graphics for the objective of clinical care. Teledentistry is also a subset of telehealth that is making a considerable impact in oral health care services.

If you want to have a real-time consultation with a dentist, you can use the video connectivity feature of teledentistry. Otherwise, you can exchange relevant clinical information and images through the store and forward feature of teledentistry. It is up to you and the way you want to seek the service of a dentist. While going through the features of teledentistry, you may be questioning how one experiences a teledentistry visit. A teledentistry visit is like a standard dental visit at a traditional clinic. First, the dentist receives the patient’s dental history and medical record. Along with this, the dentist also collects images the patient has taken through an intraoral camera. After collecting all this information, an appointment with the patient is scheduled.

Teledentistry services can be accessed through the dental app. This app has been offered by Dentulu to deliver convenient dental care services. Moreover, Dentulu has been providing unique dental consultations by the most experienced dentists. By using the teledentistry feature of Dentulu dental app, one can consult the dentist regarding their oral issues. People can even consult the care professionals through teledentistry to seek advice on whether their case is serious enough to warrant an in-person visit to the clinic.

The strength of teledentistry is that without seeing the patient in-person, the dentist can provide preventive and diagnostic services. Teledentistry is also a great tool for inter-professional communication due to its authentic and reliable communication features. The user’s privacy and confidentiality are taken care of with absolute security. That is why it is advised to use the Dentulu dental app and medical care from the comfort of your home. Our objective is to prevent unnecessary visits to healthcare centers and empower patients to use teledentistry to get timely and effective oral care services.

For instance, in December 2020, DialCare introduced its new teledentistry program offering 24/7 access to its licensed dentists in the US through phone or video consultation. Teledentistry has witnessed a surge during the COVID-19 crisis as it has helped individuals to seek medical attention from the convenience and safety of their home and not to risk infection by entering a populated clinic. mHealth technology is being developed to disseminate medical information or health data widely to practitioners and patients as well.

Some of the key players operating in the teledentistry Industry include ViDe Virtual Dental; Koninklijke Philips N.V; TheTeleDentists; MouthWatch, LLC; Denteractive Solutions, Inc.; Patterson Companies, Inc.; Virtudent, Inc.; Dentulu; HealthTap, Inc.; and e-DENTECH.

References:

https://www.theinsightpartners.com/pr/teledentistry-market

https://www.dentulu.com/explore-the-potential-of-teledentistry/

Dialysis Catheters: To Surge In The Near Future

2021-02-19T12:07:03.761Z

Dialysis catheters are special tunnel-type catheters as they are placed under the skin. These catheters are usually of two types that include cuffed and non-cuffed. Non-cuffed tunneled catheters are generally used for emergencies and for short periods. These catheters are artificial indwelling transcutaneous conduits that are used for accessing the intravascular space during renal replacement therapy.

Dialysis Catheter is also known as tunneled catheter and is placed under the skin. The catheter has double tubes with separate openings. There are two types of opening for the dialysis catheter namely as red and blue. The red opening is the arterial that draws blood from your vein whereas the blue opening of the catheter allows clean blood to return to the body. It is essential to take care of the catheter so that it lasts longer and prevent problems

Download Free Sample PDF Brochure Here

Image Credit: azuravascularcare

The catheters are used in the medical condition of hemodialysis that occurs due to the failure of kidneys and thus losing the ability to remove the additional fluidic content from the body and clean the blood. Dialysis catheters provide an alternative to gain an access to reach the blood to perform hemodialysis. It is imperative that the catheter dressings are clean and dry before the procedure. Simultaneously, the region where the hemodialysis catheters are inserted is also sterilized and the process is carried out with air not allowed to enter the device. The haemodialysis catheters are placed in the central arteries of the patients whose condition do not support the usage of AV fistulae. The preferred site for this procedure is internal jugular vein but it is advisable to look for another catheter site as well that ensures sufficient blood flow for dialysis.

Dialysis catheters are divided into two categories, one preferred for extracorporeal modes of renal replacement therapy that include haemodialysis and the second one for peritoneal dialysis. The catheters of the first category bore central venous lines to extract blood from the patient and ultimately return to their body. On the other hand, catheters used in peritoneal dialysis allows the fluid or dialysate to enter the intraperitoneal space to get in contact with the membrane.

Vascular access for the hemodialysis process is gained through an arteriovenous (AV) fistula, arteriovenous (AV) graft, or dialysis catheter (TDC). AV fistulas and AV grafts are designed for long-term use, while dialysis catheters are designed for short-time use. There exist two types of dialysis catheters: tunneled and non-tunneled dialysis catheters. Non-tunneled catheters may be cuffed or non-cuffed. Hemodialysis catheter is a soft tube inserted into a vein either in the neck, chest, or leg (close to groin). It is divided into two after the tube exits the body. Vascular access is of importance to the treatment. It is likely to be vulnerable to infections and clotting of blood, which are generally the leading cause of catheter dysfunction. A majority of hemodialysis catheters are inserted and fixed onto the anterior chest wall when the patient holds a supine position.

Considerations with Health and Wellness Supplements

2021-02-05T07:28:02.105Z

Dietary supplements were available to people for the first time in the 1940s. People lined up at what was then the ‘drug store’ to get their supplies of what deemed the ‘super pills’ boasting to improve health and wellness. That same philosophy carries over to today.

A majority of Americans have a variety of capsules filling their bathroom cabinets or counters, with most taking at least one each day to fight a deficiency in vitamins or decrease the risk for a specific disease. Some are simply being proactive concerning overall health using a supplement that touts that ability.

The volume and mix of suggestions make the decision on which is the best for you challenging. Many touts as beneficial for wellness, but the evidence is sporadic and learning what is the most advantageous and which has the potential for harm is critical.

Download Free PDF Brochure Here

Wellness supplements are incredibly popular. Sales of supplementary vitamins have grown sharply during the pandemic as people become more aware of how their overall health can influence how they react to times of illness.

Although vitamin supplements cannot purport to cure any ailments or prevent aging and sickness, they can give the body the chemical elements which many of us lack in our diets. While we have access to all sorts of healthy foods and activities, we live in a strange epoch where we don’t always have the ability to access the right nutrients. The wellness industry claims to be giving a helping hand to the modern person in this regard, allowing them to achieve the total health that they need.

Most people are trying to engage in a healthy lifestyle inclusive of a nutritional diet plan and exercise plan. A majority of those indulging in clean eating take it a step further with dietary supplements. The idea is that there are additional health benefits provided in these ingredients.

Some of those that deem among the most beneficial:

1. Pregnant women benefit from folic acid, which has the potential of reducing congenital disabilities.

2. Aiding in blood and nerve cell health, prevention of anemia, and producing DNA is Vitamin B12.

3. We can get stronger bones with the use of Vitamin D.

4. Cell damage prevention is possible with Vitamin C and Vitamin E.

5. Bone health is promoted through the use of calcium.

6. Heart health has support with the help of fish oil.

7. Age can bring vision loss due to macular degeneration, which zinc may slow down, and it will also contribute to skin health. Vitamin A can also slow down vision loss due to the disease.

8. The claim is that jet lag can be counteracted with melatonin.

The claims are not clearly proven per scientific evidence despite much research that has taken place on vitamins and minerals. Most studies completed suggest that multivitamins aren’t capable of allowing people a longer lifespan, decrease the likelihood for diseases including cancer or heart disease or diabetes, nor is there evidence that they can slow down a cognitive decline.

DNA Analysis in the Government Sector

2021-02-04T08:59:33.550Z

DNA analysis is a forensic technique employed to identify individuals by characteristics of their DNA. It can be used to identify individuals in paternity testing, criminal investigations, disaster victim identification, archaeological research, and determining genetic links to diseases. In forensic DNA analysis, DNA is collected from blood, semen, vaginal fluid, nasal secretions, and hair with roots.

DNA Analysis in the Government Sector is a type of forensic technique used to identify individuals by their DNA characteristics. It can be used to identify individuals in criminal investigations, Paternity testing, archaeological research, disaster victim identification and determining genetic links to various diseases.

Download PDF Brochure Here https://bit.ly/3pPH9IF

The key players that operate in this market include Lockheed Martin Corporation, NEC Corporation, M2SYS Technology, MorphoTrust USA, Ultra Electronics Forensic Technology, NetBio, Inc., EyeLock LLC, 3M Company, A-T Solutions, Inc., and Stanley Black & Decker, Inc.

The expansion of DNA collection could fundamentally alter the stated purpose of genetics collection. DNA collection assists in the investigation and prosecution of serious crimes. Instead, it could serve as a tool for mass government surveillance and tracking.

The DNA Analysis in the Government Sector Market is segmented on the basis of type, application and end user. On the basis of type the market is segmented as, restriction fragment length polymorphism, short tendem repeat analysis, single nucleotide polymorphism analysis, others. On the basis of application the market is segmented as, forensics, law enforcement. And on the basis of end user the market is segmented as, homeland security, defense sector.

Future developments in the field of genetic testing might one day make it possible to predict things such as a person’s addictive behaviors and their temperament through DNA. This will erode our privacy as time goes on.

The federal government already collects and stores other biometric markers such as fingerprints. Forcing people to submit DNA for civil immigration enforcement purposes is an unnecessary, expensive, and invasive practice with growing consequences for non-citizens and citizens alike. And allowing the government to find new reasons to justify the collection of genetic information increases the likelihood that more and more of us will be subjected to similar practices in the future.

Breakthrough In Hemophilia Treatment

2021-01-23T09:13:40.318Z

Hemophilia is a condition where blood does not clot, and this condition is normally inherited. The condition is caused due to defects in a gene of the X chromosome, which is a clotting factor. Generally, the diseases are widely seen in males as the X chromosome is inherited from mother to baby boy. The disease is widely treated with replacement therapy and gene therapy. The other treatment which is used is medication. However, there are ways to reduce the risk of the condition, which include regular exercise and others. The condition can be prevented by taking preventive treatment by injection of clotting factor VIII for hemophilia A, or IX for hemophilia B.

In Italy, according to the data of the National Center for Biotechnology Information (NCBI) in 2017, the number of registered people with bleeding disorders increased from about 7000 in 2000 to around 8500 in 2011 and more than 11,000 in 2015. The trend is due to an upsurge in the number of patients who are recorded, mainly in those with vWD type 1, mild hemophilia, or other factor deficiencies.

Download PDF Brochure of Study Here

A wide variety of hemophilia treatment is available as adjunctive measures to improve hemophilia if residual bleeding persists despite the correct application of conventional methods for hemorrhage control. Plasma-derived coagulation factor hemophilia treatment is considered to be active agents that participate in the coagulation cascade to form fibrin clots and are effective to make an intact coagulation system. Plasma is the liquid part of blood. It is pale yellow or straw-colored with proteins such as antibodies, albumin, and coagulation factors. There are several target factor drug products made from plasma proteins of human.

Since the late 1980s, hemophilia treatment has become safer and more effective. Hepatitis C virus and HIV have been eliminated from plasma-derived factors and recombinant products have been introduced for hemophilia B patients. In addition, prophylaxis has become standard for preventing bleeding instead of episodic treatment in which patients only receive clotting factors in response to a bleeding episode.

In particular, rIX-FP is a recombinant fusion protein that links FIX with recombinant albumin, a highly stable protein. Additionally, it uses the neonatal Fc receptor to prevent the protein’s degredation and induce its recycling. The Phase 3 study of rIX-FP showed a marked increase (4.3 times) in the factor half-life compared with traditional recombinant FIX product. While with twice-a-week injections of FIX concentrates the FIX lowest levels were 1% of normal levels, with rIX-FP weekly injections the FIX lowest levels were 20% and with 14-day injections they were 12% of normal levels.

In recent years, researchers have developed different technologies that prolong the half-life (durability) of the FIX proteins. In 2014, the U.S. Food and Drug Administration (FDA) approved the first of these recombinant products, which consisted of a fusion protein containing the FIX protein and a neonatal protein (neonatal Fc receptor) with increased stability. Also in 2014, Collins and colleagues published a study with the results of a Phase 3 trial assessing another recombinant FIX product, a glycoPEGylated FIX.

References:

https://www.theinsightpartners.com/reports/hemophilia-treatment-market

https://hemophilianewstoday.com/2016/08/22/new-era-hemophilia-b-treatment/

Troubleshooting Complications of Vascular Access Devices

2021-01-23T08:53:53.165Z

The use of intravascular (IV) drugs and fluids has increased significantly in the past three decades due to their proven effectiveness in treating a wide array of diseases. This treatment modality necessitates long-term use of vascular access devices (VADs); however, maintaining vascular access throughout the course of treatment can be a challenge. Serious complications may develop or treatment delayed if vascular access cannot be maintained. Phlebitis and extravasation are other potential complications when smaller, more fragile blood vessels are used. Treatment often becomes a painful, dreaded ordeal especially for patients with limited or damaged blood vessels.

Vascular Access Devices are used for diagnostic or therapeutic reasons such as, central venous pressure readings, fluids, total parental nutrition, blood sampling, administration of medication, and blood transfusion. The vascular access devices are inserted into veins through central vessels or peripheral vessels.

Download PDF Brochure of Study Here

Image Credit: oncologynurseadvisor

Selecting the appropriate device, providing continuous maintenance care, and troubleshooting complications requires specialized knowledge. A wide array of vascular access devices is available, and every device incurs a risk of complication. Although insertion complications can be life threatening, they occur less frequently1-4 .Catheter-related infections and occlusions are the most serious complications, as well as the most frequently reported.5 Therefore, this article will focus on catheter-related infections and occlusions.

Peripherally inserted central catheters (PICCs), tunnel catheters, and implantable ports are the types of long-term VADs used.6-7 They are referred to as long-term because the catheter tip lies in the distal third of the superior vena cava, and the device can be maintained for months to years.3 Despite the unique design of each VAD, all types can be used to administer fluids, medication, blood products, and hyperalimentation or to obtain blood samples. VADs are available in single or double lumen design, with an open or one-way valve catheter distal tip. Newer, technologically advanced devices have systems that allow for power injection of contrast material.7

Central venous/vascular access devices are small, flexible tubes placed in large veins for people who require frequent access to the bloodstream. Venous access devices that can be implanted under the skin were introduced in 1982. They allow medications to be delivered directly into larger veins, are less likely to clot, and can be left in for long periods. The CVAD may contain one or two tubes. When a CVAD contains two tubes, it is called a double or dual lumen catheter and may also be used for injecting contrast for CT or MRI scans (depending on type of CVAD).

The segmentation of the market is done on the basis of the type, application and end user. The type segment is classified into two major type central vascular devices and peripheral vascular access devices. Further, central vascular access devices include peripherally inserted central catheter (PICC), tunneled central venous catheter, percutaneous non-tunneled catheter, implanted port. The peripheral vascular access devices segment include short vascular access devices, midline vascular access devices, and subcutaneous infusions. The application segment for the vascular access devices is segmented as fluid & nutrition administration, drug administration, diagnostics & testing, and blood transfusion. The end user segment is classified as hospitals, ambulatory surgery centers and clinics. Thus, the technological advancements in vascular access devices by application and end user are driving the vascular access devices market due to rapid usage of the devices for the treatments, therapies and diagnosis.

References:

https://www.theinsightpartners.com/reports/vascular-access-devices-market

https://www.oncologynurseadvisor.com/home/departments/ce-courses/troubleshooting-complications-of-vascular-access-devices/

Vascular Bypass Revolution

2021-01-22T11:52:55.879Z

A vascular bypass is a surgical procedure performed to redirect blood flow from one area to another by reconnecting blood vessels. Often, this is done to bypass around a diseased artery, from an area of normal blood flow to another relatively normal area. The other end is attached to an artery in your lower leg. The blood now flows through the graft, instead of through the section of the artery that was narrow or blocked. Improving the blood flow to your foot can relieve pain and help to heal any open areas (ulcers) on your foot. This surgery usually takes 3 to 4 hours.

The vascular bypass allows a blocked artery to be bypassed by implanting a vessel removed from the patient, and this is done in order to create a deviation in circulation. However, in 50% of cases, excessive vascular cell proliferation, called hyperplasia, occurs around the suturing site of the transplanted vessel. Hyperplasia then leads to a decrease in blood flow within five years following the operation, requiring a new surgery.

Download PDF Brochure of Study Here

Image Credit: cvtsc

Peripheral vascular bypass is named for the artery that will be bypassed and the arteries that will receive the rerouted blood. The three common vascular bypass surgeries are: aortobifemoral (reroutes blood from the abdominal aorta to the two femoral arteries in the groin), femoropopliteal (reroutes blood from the femoral to the popliteal arteries above or below the knee), and femorotibial (which reroutes blood between the femoral artery and the tibial artery).

The life of a surgical bypass depends on the health of your arteries, the type of graft used (natural last longer than synthetic), and other health factors such as whether you smoke, or have diabetes or kidney failure.

The obstructed blood vessel is typically caused by peripheral artery disease (PAD). PAD occurs when plaque builds up on the walls of the arteries (atherosclerosis). This blockage reduces the normal flow of blood that carries oxygen and nutrients to the lower extremities. This causes cells and tissue in the legs and feet to die from lack of oxygen and nutrition. Normal growth and cell repair cannot take place, which can lead to gangrene in the limbs and subsequent amputation in the worst cases.

Dogma in vascular bypass technique says to obtain proximal and distal control. This means that in a vessel with flow through it, a surgeon must be have exposure of the furthest and nearest extents of the blood vessel in which the bypass is being created, so that when the vessel is opened, blood loss is minimized. After the necessary exposure, clamps are usually used on both the proximal and distal end of the segment. Exceptions exist where there is no blood flow through the target vessel at the area of proposed entry, as is the case with an intervening occlusion.

Wants More Info | Download PDF Copy of This Study

Genetic Modification Therapies – Clinical Applications & Technology Platforms

2021-01-16T09:33:48.269Z

Genetic modification therapies are changing the landscape of medicine. These advanced therapies have the unprecedented ability to offer a one-time cure for severe, debilitating diseases that were previously untreatable. BCC Research found that this industry is segmented by technology platform, delivery method (viral versus nonviral), and clinical application. This specialization enables companies to build significant barriers to entry and competitive advantage.

Genetic modification therapy incorporates a functional gene into a cell-based therapy. The genetic modification generally occurs outside the body, but the resulting genetic change to the patient's DNA is permanent. The active payload comprise of the gene encoding for production of the therapeutic protein and gene controls that regulates production of the therapeutic gene. The vector, which may be either non-viral or viral, delivers the gene and gene control payload to the cells which are to be genetically modified. The most common cell types include T cells, and HSCs. Genetic modification has brought a milestone into medicine. Genetic modification is very crucial in treating severe diseases.

Download PDF Brochure Study Here

Image Credit: creative-biolabs

Strong patent and licensing arrangements also contribute to these competitive positions. Manufacturing to meet the large-scale demands of the industry will play an important role in the future. The interest level in corporate partnerships has been enhanced by recent clinical successes and regulatory approvals for genetic modification therapy candidates. Industry alliances have been centered on several objectives, including access to genetic modification therapy technologies by large pharma/biotech, access to delivery technologies, and entry into new therapeutic markets.

Key factors for meeting revenue forecasts include continuing demonstration of genetic modification therapy efficacy and safety in clinical settings, migration to earlier-line settings in cancer, and success in efforts to standardize and scale up the manufacture of viral delivery vectors. The following sections examine the main genetic modification therapy platform technologies: gene therapies, genetically modified cell therapies, RNA therapies, and gene editing.

A rich late-stage pipeline of gene therapies is being developed for a wide range of disease categories. In the next 5 years, gene therapy is poised to exert a significant influence on genetic modification therapies. Gene therapies seek to permanently replace defective genes in a cell’s DNA. This can restore cellular function and has the potential to totally eliminate a disease. Monogenic diseases, for which a specific disease-causing gene can be identified, are well-suited for gene therapies.

To be successful, gene therapy candidates must meet important clinical criteria: 1) the pathogenic mechanism should be clear and addressable, 2) the target organ must be accessible to the gene therapy, and 3) there must be a compelling, unmet medical need. Luxturna, which is the first gene therapy to be approved by the FDA, fully meets these criteria. Luxturna is indicated for biallelic RPE65-mediated inherited retinal disorders. In this indication, mutations in the RPE65 gene is the clear and addressable pathogenic mechanism. The target organ (the eye) is easily accessible to the gene therapy, which uses an AAV2 viral vector to carry the correct version of this gene. Finally, there is a clear and pressing medical need for therapies that can restore functional vision in children and adults who have this disorder.

References:

https://www.theinsightpartners.com/reports/genetic-modification-therapies-market/

https://drug-dev.com/genetic-modification-therapies-clinical-applications-technology-platforms/